Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumour × toripalimab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 33 Carcinoma, Non-Small-Cell Lung 24 Carcinoma, Hepatocellular 19 Esophageal Squamous Cell Carcinoma 18 Triple Negative Breast Neoplasms 17 Squamous Cell Carcinoma of Head and Neck 17 Breast Neoplasms 15 Melanoma 13 Advanced Solid Tumor 13 Stomach Neoplasms 12 Small Cell Lung Carcinoma 11 Uterine Cervical Neoplasms 10 Neoplasms 10 Colorectal Neoplasms 10 Recurrence 8 Carcinoma, Transitional Cell 8 Carcinoma, Renal Cell 7 Solid Tumor 6 Sarcoma 6 Head and Neck Neoplasms 6 Neoplasm Metastasis 5 Liver Neoplasms 5 Esophageal Neoplasms 5 Rectal Neoplasms 4 Pancreatic Neoplasms 4 Laryngeal Neoplasms 4 Hypopharyngeal Neoplasms 4 Ovarian Neoplasms 3 Lymphoma 3 Lung Neoplasms 3

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡